Abstract:OBJECTIVE:It is well established that regional cerebral metabolic rates for glucose assessed by [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in patients with Alzheimer's disease in the mental resting state (eyes and ears covered) provide a sensitive, in vivo metabolic index of Alzheimer's disease dementia. Few studies, however, have evaluated longitudinal declines in regional cerebral glucose metabolism in patients with dementia caused by Alzheimer's disease. In addition, the available studies have not used recently developed brain mapping algorithms to characterize the progression of Alzheimer's disease throughout the brain, and none considered the statistical power of regional cerebral glucose metabolism in testing the ability of treatments to attenuate the progression of dementia.METHOD:The authors used FDG PET and a brain mapping algorithm to investigate cross-sectional reductions in regional cerebral glucose metabolism, longitudinal decline in regional cerebral glucose metabolism after a 1-year follow-up, and the power of this method to evaluate treatments for Alzheimer's disease in patients with mild to moderate dementia. PET scans were initially acquired in 14 patients with Alzheimer's disease and 34 healthy comparison subjects of similar age and sex. Repeat scans were obtained in the patients 1 year later. Power analyses for voxels showing maximal decline over the 1-year period in regional cerebral glucose metabolism (mg/100 g per minute) were computed to estimate the sample sizes needed to detect a significant treatment response in a 1-year, double-blind, placebo-controlled treatment study.RESULTS:The patients with Alzheimer's disease had significantly lower glucose metabolism than healthy comparison subjects in parietal, temporal, occipital, frontal, and posterior cingulate cortices. One year later, the patients with Alzheimer's disease had significant declines in glucose metabolism in parietal, temporal, frontal, and posterior cingulate cortices. Using maximal glucose metabolism reductions in the left frontal cortex, we estimated that as few as 36 patients per group would be needed to detect a 33% treatment response with one-tailed significance of p</=0.005 and 80% power in a 1-year, double-blind, placebo-controlled treatment study.CONCLUSIONS:These findings indicate that brain metabolism as assessed by FDG PET during mental rest is a sensitive marker of disease progression in Alzheimer's disease over a 1-year period. These findings also support the feasibility of using FDG PET as an outcome measure to test the ability of treatments to attenuate the progression of Alzheimer's disease.

Longitudinal Changes in Serum Glucose Levels Are Associated with Metabolic Changes in Alzheimer's Disease Related Brain Regions

Association Between Longitudinal Increases in Serum Glucose and Metabolic Decline in Azheimer’s Disease-Related Brain Regions (P6.321)

Higher Serum Glucose Levels Are Associated with Cerebral Hypometabolism in Alzheimer Regions

Investigating the Association Between Fasting Serum Glucose Levels and Cerebral Metabolic Rate for Glucose in Brain Regions Affected by Alzheimer's Disease

Association Between Higher Fasting Serum Glucose Levels and the Pattern of Lower Regional Gray Matter Volumes in Cognitively Normal Adults

Higher Serum Total Cholesterol Levels in Late Middle Age Are Associated with Glucose Hypometabolism in Brain Regions Affected by Alzheimer'S Disease and Normal Aging

Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer’s Disease Treatment Studies

Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI

Relationship Between Longitudinal, Structural Magnetic Resonance Imaging and [18f]fluorodeoxyglucose Positron Emission Tomography Data From The Alzheimer'S Disease Neuroimaging Initiative Study

Categorical and Correlational Analyses of Baseline Fluorodeoxyglucose Positron Emission Tomography Images from the Alzheimer's Disease Neuroimaging Initiative (ADNI)

P4‐053: Relationship Between Longitudinal, Structural Magnetic Resonance Imaging and [18f]fluorodeoxyglucose Positron Emission Tomography Data from the Alzheimer'S Disease Neuroimaging Initiative Study

Elevated blood glucose levels are associated with the progression of brain hypometabolism, and HDL-C and APOE4 add to this association

Cerebral glucose metabolism in Alzheimer's disease

Associations Between Glucose Metabolism Measures and Amyloid-β and Tau Load on PET 14 Years Later: Findings From the Framingham Heart Study

Genome-Wide Association Study of Brain Alzheimer's Disease-Related Metabolic Decline As Measured by [18F] FDG-PET Imaging.

Association Between Cerebral Patterns of Fibrillar Beta-Amyloid Burden and Glucose Hypometabolism in Cognitively Normal Older Adults at Three Levels of Genetic Risk for Late-Onset Alzheimer's Disease

Brain imaging evidence of preclinical Alzheimer's disease in normal aging

Association of brain amyloid accumulation and glucose hypometabolism with cognition domain of language: Neuropsychology/Neuropsychological correlates of physiologic markers of cognitive decline/Dementia

Tracking the Decline in Cerebral Glucose Metabolism in Persons and Laboratory Animals at Genetic Risk for Alzheimer's Disease

Topographic extent of cerebral hypometabolism predicts time of conversion from aMCI to Alzheimer's disease: Data from the Alzheimer's Disease Neuroimaging Initiative

Impact of plasma glucose level on the pattern of brain FDG uptake and the predictive power of FDG PET in mild cognitive impairment